Risk factors for the postoperative recurrence of ulcerative colitis-associated colorectal cancer

被引:3
作者
Horio, Yuki [1 ,2 ]
Uchino, Motoi [1 ]
Igeta, Masataka [3 ]
Nagano, Kentaro [1 ]
Kusunoki, Kurando [1 ]
Kuwahara, Ryuichi [1 ]
Kimura, Kei [1 ]
Kataoka, Kozo [1 ]
Beppu, Naohito [1 ]
Ikeda, Masataka [1 ]
Ikeuchi, Hiroki [1 ]
机构
[1] Hyogo Med Univ, Dept Gastroenterol Surg, Nishinomiya, Hyogo, Japan
[2] Hyogo Med Univ, Dept Gastrointestinal Surg, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan
[3] Hyogo Med Univ, Dept Biostat, Nishinomiya, Hyogo, Japan
关键词
Ulcerative colitis-associated carcinoma; Surgery; Recurrence; INFLAMMATORY-BOWEL-DISEASE; PRIMARY SCLEROSING CHOLANGITIS; III COLON-CANCER; ADJUVANT CHEMOTHERAPY; AMERICAN-SOCIETY; STAGE-II; SURVEILLANCE; OXALIPLATIN; NEOPLASIA; SURVIVAL;
D O I
10.1007/s00384-023-04410-z
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
PurposeAlthough ulcerative colitis-associated colorectal cancer (UC-CRC) has been described, there are few reports regarding recurrent cases of UC-CRC. In this study, we investigated the risk factors for UC-CRC recurrence.MethodsRecurrence-free survival (RFS) was determined for 144 stage I to III cancer patients among 210 UC-CRC patients from August 2002 to August 2019. The Kaplan-Meier method was used to obtain the cumulative RFS rate, and the Cox proportional hazard model was used to extract recurrence risk factors. The interaction term between cancer stage and prognostic factors specific to UC-CRC was evaluated using the Cox model. The Kaplan-Meier method was applied by cancer stage to the UC-CRC-specific prognostic factors for which interaction effects were indicated.ResultsThere were 18 cases of recurrence involving patients with stage I to III cancer, and the recurrence rate was 12.5%. The cumulative 5-year RFS rate was 87.5%. Multivariable analysis showed that age at surgery (hazard ratio (HR): 0.95, 95% CI: 0.91-0.99, p = 0.02), undifferentiated carcinoma (HR: 4.42, 95% CI: 1.13-17.24, p = 0.03), lymph node metastasis (HR: 4.11, 95% CI: 1.08-15.69, p = 0.03), and vascular invasion (HR: 8.01, 95% CI: 1.54-41.65, p = 0.01) were significant risk factors for recurrence. Patients with stage III CRC in the young adult (age < 50 years) group had a significantly worse prognosis than those in the adult (age >= 50 years) group (p < 0.01).ConclusionAge at surgery was identified as a risk factor for UC-CRC recurrence. Young adult patients with stage III cancer may have a poor prognosis.
引用
收藏
页数:11
相关论文
共 41 条
[1]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[2]   European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies [J].
Annese, Vito ;
Beaugerie, Laurent ;
Egan, Laurence ;
Biancone, Livia ;
Bolling, Claus ;
Brandts, Christian ;
Dierickx, Daan ;
Dummer, Reinhard ;
Fiorino, Gionata ;
Gornet, Jean Marc ;
Higgins, Peter ;
Katsanos, Konstantinos H. ;
Nissen, Loes ;
Pellino, Gianluca ;
Rogler, Gerhard ;
Scaldaferri, Franco ;
Szymanska, Edyta ;
Eliakim, Rami .
JOURNAL OF CROHNS & COLITIS, 2015, 9 (11) :945-965
[3]   Stage at Diagnosis and Survival of Colorectal Cancer With or Without Underlying Inflammatory Bowel Disease: A Population-based Study [J].
Arhi, Chanpreet ;
Askari, Alan ;
Nachiappan, Subramanian ;
Bottle, Alex ;
Arebi, Naila ;
Athanasiou, Thanos ;
Ziprin, Paul ;
Aylin, Paul ;
Faiz, Omar .
JOURNAL OF CROHNS & COLITIS, 2021, 15 (03) :375-382
[4]   Increasing Disparities in the Age-Related Incidences of Colon and Rectal Cancers in the United States, 1975-2010 [J].
Bailey, Christina E. ;
Hu, Chung-Yuan ;
You, Nancy ;
Bednarski, Brian K. ;
Rodriguez-Bigas, Miguel A. ;
Skibber, John M. ;
Cantor, Scott B. ;
Chang, George J. .
JAMA SURGERY, 2015, 150 (01) :17-22
[5]   Gastroenterology 2 - Inflammatory bowel disease: clinical aspects and established and evolving therapies [J].
Baumgart, Daniel C. ;
Sandborn, William J. .
LANCET, 2007, 369 (9573) :1641-1657
[6]   American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J].
Benson, AB ;
Schrag, D ;
Somerfield, MR ;
Cohen, AM ;
Figueredo, AT ;
Flynn, PJ ;
Krzyzanowska, MK ;
Maroun, J ;
McAllister, P ;
Van Cutsem, E ;
Brouwers, M ;
Charette, M ;
Haller, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3408-3419
[7]   Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease [J].
Brackmann, Stephan ;
Andersen, Solveig N. ;
Aamodt, Geir ;
Langmark, Froydis ;
Clausen, Ole P. F. ;
Aadland, Erling ;
Fausa, Olav ;
Rydning, Andreas ;
Vatn, Morten H. .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2009, 44 (01) :46-55
[8]   Cancer surveillance in ulcerative colitis [J].
Chambers, WM ;
Warren, BF ;
Jewell, DP ;
Mortensen, NJM .
BRITISH JOURNAL OF SURGERY, 2005, 92 (08) :928-936
[9]   Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview [J].
Choi, Chang-Ho Ryan ;
Rutter, Matthew D. ;
Askari, Alan ;
Lee, Gui Han ;
Warusavitarne, Janindra ;
Moorghen, Morgan ;
Thomas-Gibson, Siwan ;
Saunders, Brian P. ;
Graham, Trevor A. ;
Hart, Ailsa L. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 (07) :1022-1034
[10]   Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease [J].
Collins, P. D. ;
Mpofu, C. ;
Watson, A. J. ;
Rhodes, J. M. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (02)